Evidence map›Paper›PMID 29592811›Full record

ArticleJournal of biomedical science2018

Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma.

I-Ting Tsai, Ching-Chuan Kuo, Jing-Ping Liou, Jang-Yang Chang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomedical science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

I-Ting TsaiNational Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
Ching-Chuan KuoInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan.
Jing-Ping LiouCollege of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Jang-Yang ChangNational Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan. jychang@nhri.org.tw.
National Cheng Kung University · TWNational Health Research Institutes · TWTaipei Medical University · TW

Funding

Ministry of Health and Welfare CA105-SP-01Ministry of Science and Technology MOST-105-2320-B-400-011-MY3Ministry of Science and Technology MOST 105-2325-B-400-001National Health Research Institutes CA-105-PP-22
6 · The paper itself

Abstract

backgroundTumor hypoxia-induced epithelial-mesenchymal transition (EMT) is critical in promoting cancer metastasis. We recently discovered a novel microtubule inhibitor, MPT0B098, that employs a novel antitumor mechanism. It destabilizes hypoxia-inducible factor (HIF)-1α mRNA by blocking the function of human antigen R. Thus, we proposed that MPT0B098 modulates hypoxia-induced EMT.

methodsIn vitro IC

resultsMPT0B098 significantly inhibited HIF-1α expression, epithelial-to-mesenchymal morphology changes, and migratory ability in the human head and neck squamous cell carcinoma cell line OEC-M1. Furthermore, after MPT0B098 treatment, the expression of two mesenchymal markers, vimentin and N-cadherin, was downregulated under hypoxic conditions. Moreover, MPT0B098 suppressed hypoxia-induced EMT in part by inhibiting EMT-activating transcription factors, Twist and SNAI2/Slug. In addition, the inhibition of hypoxia-induced F-actin rearrangement and focal adhesion kinase phosphorylation may have contributed to suppression of EMT by MPT0B098in OEC-M1 cells. MPT0B098 significantly inhibited transforming growth factor(TGF)-β-induced phosphorylation of receptor-associated Smad2/3 by downregulating TGF-β mRNA and protein expression.

conclusionsTaken together, this study provides a novel insight into the role of MPT0B098 in inhibiting hypoxia-induced EMT, suggesting its potential use for treating head and neck cancers.

Indexed as

Carcinoma, Squamous CellCell Line, TumorEpithelial-Mesenchymal TransitionHead and Neck NeoplasmsHumansHypoxiaHypoxia-Inducible Factor 1, alpha SubunitIndolesSquamous Cell Carcinoma of Head and NeckSulfonamidesTubulin ModulatorsHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitIndolesMPT0B098SulfonamidesTubulin ModulatorsEpithelial to mesenchymal transitionHead and neck cancerHypoxiaMicrotubule inhibitorTGF-β

Identifiers

PMID29592811
PMCPMC5875002
OpenAlexW2794566548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.